Form 4: Relay Therapeutics Executive Sells Shares for Tax

Donald A. Bergstrom, President of R&D at Relay Therapeutics, sold 1,490 shares to cover tax obligations related to RSU vesting.

Summary

• Donald A. Bergstrom, President of R&D at Relay Therapeutics, Inc. (RLAY), executed a sale of 1,490 shares of common stock.
• The transaction occurred on April 28, 2026, at a price of $14.79 per share.
• The sale was conducted to satisfy mandatory tax withholding obligations resulting from the vesting of 5,012 restricted stock units (RSUs) on April 27, 2026.
• Following this transaction, the reporting person maintains beneficial ownership of 418,557 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was purely administrative and non-discretionary to cover tax liabilities.

Positives

• The transaction was non-discretionary and specifically executed to satisfy tax obligations, indicating it was not a signal of lack of confidence in the company.

Negatives

• Reduction in the direct equity stake held by a key executive, though the impact is minimal relative to total holdings.

Risks

• Reliance on RSU vesting schedules for executive compensation may lead to periodic, non-discretionary selling activity.

Future Outlook

No forward-looking guidance or strategic outlook provided in this filing.

Industry Context

StockSavvy.ai notes that this is a routine 'sell-to-cover' transaction common in the biotechnology sector, where executives frequently receive equity-based compensation that triggers tax events upon vesting.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for handling tax withholding on equity compensation.

Stakeholder Impact

• Minimal impact on shareholders as the sale was mandatory and limited in scope.

Key Dates

Keywords

Relay Therapeutics, RLAY, Insider Trading, Form 4, Biotech, Executive Compensation